Roche looks to compete against a blockbuster with its newly approved vision drug

Roche looks to compete against a blockbuster with its newly approved vision drug

Source: 
Stat
snippet: 

Roche announced Friday that it received Food and Drug Administration approval for the first-ever bispecific antibody treatment for two common causes of vision loss, setting the stage for a battle with Regeneron, which markets a blockbuster drug in this space.